|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.21 EUR | -5.47% |
|
-12.45% | -11.68% |
| Apr. 10 | Transgene: presents vaccine results at AACR | CF |
| Mar. 28 | Transgene CFO Steps Down; Successor Assumes Office | MT |
Transgene SA reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was EUR 7.9 million compared to EUR 10.34 million a year ago. Net loss was EUR 22.33 million compared to EUR 32.8 million a year ago.
Basic loss per share from continuing operations was EUR 0.22 compared to EUR 0.33 a year ago. Diluted loss per share from continuing operations was EUR 0.22 compared to EUR 0.33 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -11.68% | 130M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
TRANSGENE 
